Wegovy (Semaglutide) vs Foundayo (Orforglipron) for Weight Loss
For most patients with obesity or overweight with weight-related complications, Wegovy (semaglutide 2.4 mg subcutaneous weekly) should be prioritized over Foundayo (orforglipron) based on superior weight loss efficacy, established cardiovascular benefits, and better tolerability. 1
Evidence-Based Recommendation Framework
Primary Considerations
Efficacy Profile:
- Wegovy achieves 14.9-16.9% total body weight loss at 68 weeks, with 83.5% of patients achieving ≥5% weight loss and 66.1% achieving ≥10% weight loss 1, 2
- Foundayo achieves 11.2% total body weight loss at 72 weeks, with 54.6% achieving ≥10% weight loss 3
- Direct comparison data shows oral semaglutide 25 mg produces 3.2% greater weight loss than orforglipron 36 mg (the bioequivalent dose to Foundayo 17.2 mg) 4
The AGA guidelines explicitly state that "semaglutide 2.4 mg may be prioritized over other approved AOMs for the long-term treatment of obesity for most patients" given its magnitude of net benefit 1
Cardiovascular and Metabolic Benefits
Wegovy has proven cardiovascular benefits:
- 20% reduction in major adverse cardiovascular events (MACE) in patients with established CVD without diabetes (SELECT trial) 5
- FDA-approved for secondary cardiovascular risk reduction 5
- Prevents progression from prediabetes to type 2 diabetes 5
- Improves heart failure with preserved ejection fraction (HFpEF) 5
Foundayo lacks cardiovascular outcomes data - no completed cardiovascular outcomes trials exist for orforglipron 6
Safety and Tolerability Profile
Critical safety differences favor Wegovy:
Foundayo has higher discontinuation rates:
- 9-10% discontinuation due to adverse events vs 4-5% with oral semaglutide 7
- 4.1-fold higher odds of discontinuation due to any adverse event compared to oral semaglutide 4
- 13.9-fold higher odds of discontinuation due to GI adverse events 4
Foundayo has additional safety concerns:
- Higher incidence of gastrointestinal events (58-59% vs 37-45% with semaglutide) 7
- Greater pulse rate increase (3.7-4.7 bpm vs 1.0-1.5 bpm with semaglutide) 7
- Five cases of mild pancreatitis reported in trials 3
- May reduce efficacy of oral contraceptives - requires switching to non-oral contraception for 30 days after initiation and each dose escalation 6
Wegovy's established safety profile:
- 38% higher risk of serious adverse events vs placebo, but most not drug-related 1
- Common GI effects (nausea, vomiting) manageable with gradual titration 1
- Contraindicated only in personal/family history of medullary thyroid cancer or MEN 2 1
Clinical Decision Algorithm
Choose Wegovy (First-Line) When:
- Patient can tolerate subcutaneous injections
- Established cardiovascular disease present (proven MACE reduction)
- Maximum weight loss desired (superior efficacy)
- Patient has type 2 diabetes (glucoregulatory benefits)
- Better tolerability profile needed
Consider Foundayo Only When:
- Patient has absolute contraindication to injections (needle phobia, bleeding disorder)
- Patient explicitly refuses all injectable therapies after counseling on superior efficacy
- Access/insurance barriers prevent Wegovy use
Important caveat: Even for injection-averse patients, counsel that oral semaglutide (when available at higher doses) outperforms orforglipron with better tolerability 4
Practical Implementation
Wegovy dosing:
- Start 0.25 mg weekly × 4 weeks
- Escalate monthly: 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg (maintenance)
- Gradual titration minimizes GI adverse effects 1
Foundayo dosing:
- Requires daily oral administration (vs weekly injection)
- Must be kept in original bottle protected from light 6
- If ≥7 consecutive doses missed, restart at lower dose 6
Common Pitfalls to Avoid
Don't assume oral = better adherence - Foundayo requires daily dosing vs weekly Wegovy, and has 2-4× higher discontinuation rates 4
Don't overlook contraception interactions - Foundayo uniquely reduces oral contraceptive efficacy, requiring contraceptive switching 6
Don't ignore cardiovascular benefits - Wegovy's proven MACE reduction is critical for patients with established CVD 5
Don't equate GLP-1 class effects - Despite both being GLP-1 agonists, efficacy and tolerability differ substantially between agents 4, 8
Monitor pulse rate more closely with Foundayo - 3-4× greater pulse increase than semaglutide 7
The evidence strongly supports Wegovy as the preferred agent based on superior weight loss, proven cardiovascular benefits, better tolerability, and guideline recommendations prioritizing semaglutide over other anti-obesity medications 1, 5, 4.